Plexus Ventures Assists Celon Pharma to Out-License Generic Advair® Diskus® for France

Jan 19, 2017

London, United Kingdom – Plexus Ventures is pleased to announce it served as advisor to Celon Pharma SA and Polfarmex SA in the out-licensing of Salmex® Orbicel® (fluticasone/salmeterol), a generic version of GSK’s Advair® Diskus®, to an undisclosed company for France.

Michael O’Sullivan, Managing Partner (London), the Plexus Ventures partner responsible for the project, commented: “We are extremely pleased we were able to help our client succeed in this project. This was a complex transaction requiring significant time and energy from all parties involved. We have shown once again that our persistence leads to success even in the most challenging assignments.”

About Plexus Ventures

Plexus Ventures has earned the title Business Builders in Healthcare over nearly three decades as a leading corporate and business development consultancy for healthcare industry companies. Plexus assists clients of all sizes and capabilities to achieve their strategic business development objectives. Plexus industry professionals are conveniently located in the United States, Europe and Asia-Pacific markets, enabling Plexus to benefit its clients with both local knowledge and global reach.

Trending

News

Plexus Ventures Announces Team Promotions

Philadelphia, Pennsylvania – Plexus Ventures, a prominent corporate and business development boutique for healthcare companies, is pleased to announce two promotions among its team members.Gabriele Tundo, Vice President, has been promoted to Partner. Gabriele joined...

Theresa Covert Walker joins Plexus Ventures as Vice President

Philadelphia, Pennsylvania,  June 11, 2021 – Plexus Ventures is pleased to announce the appointment of Theresa Covert Walker as Vice President based in the Pensacola area.  Theresa joins Plexus after a 27-year career at Merck & Co., bringing significant executive,...